PrEP for HIV (Human Immunodeficiency Virus)
This trial will test if providing HIV-negative participants with PrEP medicine at the IDEA Exchange will help them stay negative.
- HIV (Human Immunodeficiency Virus)
- Substance Use Disorder
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
What is the current size of the cohort taking part in this research?
"Affirmative. According to information published on clinicaltrials.gov, this medical research has been actively searching for participants since February 1st 2022 and was most recently updated in March 4th 2022. The trial needs 100 individuals at a single site."
Are there still openings available for participants in this research?
"The details posted on clinicaltrials.gov demonstrate that this medical investigation is enrolling participants, with the initial announcement made on February 1st 2022 followed by a recent update on March 4th."
What research has been conducted related to PrEP?
"Currently, 98 clinical trials are underway to investigate the efficacy of PrEP with 22 in its final phase. The epicentre of these trials is Boylston, Massachusetts but there are 1610 global locations carrying out research."
What potential risks come with taking PrEP?
"PrEP has already been approved, making it a safe and viable option. Our team at Power gave this treatment an assessment score of 3 to reflect its efficacy in the medical community."
What pathologies is PrEP typically employed to combat?
"The antiretroviral drug PrEP can be utilized to treat HIV-1, address existing infections caused by the virus, and reduce transmission."